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Aims - Sodium glucose co-transporter 2 inhibitors (SGLT2i), sulfonylureas (SU), 
and dipeptidyl peptidase-4 inhibitors (DPP4i) are added to treatment if metformin 
monotherapy does not achieve adequate glycaemic control. The comparative effects 
of these drugs on cardiometabolic risk factors in routine care are unknown.   
Materials and Methods – Using primary care data of 10,631 new-users of SU, 
SGLT2i or DPP4i with metformin from the UK Clinical Practice Research Datalink. 
We created propensity-score matched cohorts and used linear mixed models to 
describe changes in HbA1c, estimated glomerular filtration rate (eGFR), systolic 
blood pressure (BP), and body mass index (BMI) over 96 weeks. 
Results - HbA1c fell substantially after intensification for all drugs, mean change 
(mmol/mol), week 12: SGLT2i: -15.2 (95% CI-16.9,-13.5); SU: -14.3 (95% CI-
15.5,-13.2); DPP4i: -11.9 (95% CI-13.1,-10.6)). Systolic BP fell for SGLT2i users 
throughout follow-up but not DPP4i or SU (Mean change (mmHg), week 12: 
SGLT2i: -2.3 (95% CI: -3.8,-0.8); SU: -0.8 (95% CI:-1.9,+0.4), DPP4i: -0.9 (95% 
CI: -2.1,+0.2)).  
BMI decreased for SGLT2i and DPP4i treated patients, but not SU users (Mean 
change (kg/m2), week 12: SGLT2i: -0·7 (95% CI: -0.9,-0.5); SU: 0.0 (95% CI: -
0.3,+0.2), DPP4i: -0.3 (95% CI: -0.5,-0.1)).  eGFR fell at 12 weeks for SGLT2i and 
DPP4i treated patients. At 60 weeks, the fall in eGFR from baseline was similar for 
each drug class. 
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Conclusions - In routine care, SGLT2is have greater effects on cardiometabolic risk 
factors than SUs. Routine care data closely replicates the effects of diabetes drugs on 
physiological variables measured in clinical trials.  




Type 2 Diabetes Mellitus is a leading cause of morbidity and mortality worldwide, 
resulting in one million deaths worldwide in 2017.(1) Drug treatments often provide 
benefits for glycaemic control and surrogate outcomes but recently clinical trials of 
sodium-glucose cotransporter 2 inhibitors (SGLT2is), have shown substantial reductions 
in adverse cardiovascular and renal outcomes.(2-5) In these major outcome trials 
SGLT2is have been compared to placebo, contrasting with the way the drugs have been 
recommended for use in clinical practice: international guidelines have recommended 
SGLT2i as an option to intensify glycaemic control after metformin monotherapy, but 
with sulfonylurea (SU), thiazolidinedione, DPP-4 inhibitor (DPP4i) or GLP-1 receptor 
agonists as alternate choices.(6, 7)  
SGLT2is work by inhibiting reabsorption of glucose in the proximal renal tubule and 
thus lowering blood sugar levels. As well as improved glycaemic control, this results in 
weight loss, blood pressure reduction and diuresis.(8) In clinical trials of SGLT2is, the 
active treatment arm has shown lower blood pressure and better glycaemic control 
compared to patients receiving placebo.(2-5) However, there is limited evidence that 
lower blood pressure or tighter diabetic control is associated with better cardiovascular 
outcomes.(9, 10) Therefore, it is not clear if the improved clinical outcomes for SGLT2i 
treated patients are explained by improvements in known cardiovascular and renal risk 
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factors, which might also occur for other drug classes in direct comparator trials, or if 
other mechanisms exist.(11) 
Observational studies have compared major outcomes between SGLT2i users and those 
with no additional treatment, and against active comparator agents.(12-17) These studies 
also report substantial outcomes benefits for SGLT2i users but have been criticised for 
failing to adequately account for sources of bias and confounding, in particular that 
SGLT2is are prescribed to younger patients with fewer comorbidities.(18) Few 
observational studies have examined the effects of first line intensification drugs for 
type 2 diabetes on biological parameters and these have mainly focussed on comparative 
effects of drug classes on glycaemic control.(19-21) The effects of SGLT2i drugs on 
physiological variables such as blood pressure measured in routine care, and how this 
relates to the results observed within the standardised setting of clinical trials, are 
currently unknown.  
Use of both DPP4 and SGLT2i drugs for first stage intensification of control of type 2 
diabetes have been increasing rapidly in routine clinical care over recent years with wide 
variation in prescribing patterns.(22) There has been relative equipoise for choice of 
intensification drug offered by current clinical guidelines, and limited differences in the 
characteristics of people prescribed different drugs which are well understood and 
measureable.(23) This combination of circumstances means that observational data lend 
themselves to a natural experiment, making direct comparisons of medication effects on 
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important diabetes outcomes in a routine care population at the first stage of treatment 
intensification when SGLT2is are commonly used. 
Incentivised by the Quality Outcomes Framework, people with Type 2 diabetes are 
regularly monitored in United Kingdom primary care, and measures of diabetic control, 
cardiovascular risk and renal function are well recorded in routine data.(24) Therefore, 
we conducted a propensity score matched, new-user cohort study to determine the 
effects of the three most commonly used drugs for intensification of glycaemic control 
after metformin monotherapy, SGLT2i, DPP4 and SU, on measures of cardiovascular 
and renal risk.(22) 
Materials and Methods 
Data sources 
We used data from the Clinical Practice Research Datalink (CPRD) which covers 
approximately seven percent of the UK population and is representative in terms of age, 
sex and ethnicity.(25) The data contains information collected by GPs and primary care 
practitioners for routine patient care in primary care settings. Data collected includes 
demographic information, medical diagnoses, prescriptions, laboratory test results and 
diagnoses made in secondary care. Our data were linked to patient-level quintiles of 
index of multiple deprivation scores (IMD) collated in 2015 as a measure of 
socioeconomic deprivation, provided by the Office of National Statistics.(26) 




To reflect prescribing of drugs used to intensify treatment of type 2 diabetes in 
contemporary routine clinical practice, we selected a new-user cohort of adults adding 
additional treatment to metformin monotherapy (study population). We first identified a 
study population of individuals aged ≥18 years with a new record for metformin before 
any other antidiabetic medication, between Jan 2000 and July 2017. We restricted to 
people with a minimum of 12 months of prior registration in CPRD to allow complete 
data entry and ensure they were new-users of antidiabetic drugs. From this group we 
identified people prescribed one of the potential antidiabetic drug choices recommended 
by NICE at the first stage of treatment intensification, defined as the ‘index’ drug, 
between January 2014 and July 2017.  Based on previous work we excluded people 
intensifying treatment with a thiazolidinedione, insulin or glucagon-like peptide-1 
receptor agonists as these treatments have been infrequently used in recent years and/or 
fall outside the standard first-stage guidance.(22) We excluded patients who were 
pregnant before and after treatment change as guidelines are different whilst pregnant or 
breastfeeding.  
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To limit the study population to people who intensified rather than changed treatment, 
we required that a) a second prescription for the index drug was recorded within 60 days 
after the end of the first prescription, and b) that the individual received a further 
metformin prescription between the first and second prescription for an intensification 
drug. We used the date of the first prescription for the first stage intensification drug as 
baseline/study entry. Outcomes 
We chose four clinical measures that are associated with future risk of cardiovascular 
disease or diabetic complications: i) Glycosylated haemoglobin (HbA1c), ii) systolic 
blood pressure (BP), iii) body mass index (BMI) and iv) estimated glomerular filtration 
rate (eGFR).(27, 28) For each measure we extracted all test results for HbA1c, systolic 
BP, weight and height to calculate BMI, and serum creatinine to calculate eGFR using 
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.(29) We 
then created four cohorts which are subsets of the study population for each clinical 
measure (Figure 1). To be included in a cohort, patients required at least one record of 
the measure within 540 days prior to drug treatment intensification and at least one 
follow-up recording of the variable of interest. Participants in each cohort were followed 
until the first of: death, leaving the practice, prescription of an alternative drug treatment 
for type 2 diabetes, or end of study (1st July 2017). 
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Descriptive variables and covariates 
Details of our cohort methodology have been published previously.(23) Baseline 
covariates are those recorded prior to index drug prescription. We only included 
measurements within 540 days prior to baseline as older values might not reflect the 
values at the point of treatment intensification. This time point was chosen 
pragmatically based on the Quality Outcomes Framework recommendation that patients 
with diabetes have full clinical review annually, with additional time for delays in 
arranging appointments and for data-entry.(30) Medical diagnoses such as 
cardiovascular disease (CVD) and retinopathy were defined as present if they were 
listed in the medical record on or before the date of drug intensification. We defined use 
of ACE Inhibitors/Angiotensin Receptor Blockers (ACEI/ARB) or statins as any 
prescription in the year before the start of follow-up.  
Statistical analysis 
Propensity score matching 
Variables considered as potential confounders, based on previous work defining factors 
associated with drug prescription,(23) were: age, gender, ethnicity, baseline values of 
HbA1c, eGFR, BMI and systolic BP, baseline diagnosis of CVD, retinopathy or current 
smoking, quintile of IMD, time taking metformin before intensification, and the year 
that treatment was intensified.  
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Propensity score matching between the three classes of drugs was used to assemble a 
sample in which each patient receiving SGLT2i was matched to up to four DPP4i 
patients prescribed DPP4i and up to five patients prescribed SU. These matching goals 
were chosen to reflect the relative number of users in each group. Each matched set had 
to include a minimum of one patient from each of the three treatment groups being 
compared. Patients were matched without replacement on the propensity score within a 
calliper of 0·025, approximately 0·2 times the standard deviation of the propensity 
score. The estimated propensity scores were obtained from logistic regression. An 
iterative approach to the selection of confounders was taken, including a potential 
confounder in the model if required to obtain balance of the variable across treatment 
groups, as measured by the standardised mean difference, accepting imbalances up to 
0·2. We matched cohorts on their baseline measures of BMI, systolic BP, eGFR or 
HbA1c by including additional ‘exact’ matching on each variable. To account for the 
variability in the number of individuals in the matched sets, patients in incomplete sets 
were up-weighted to give each matched set equal weight.(31) Separate propensity score 
models were fitted to each sub-cohort (one for each outcome measure). Missing data in 
confounders was handled using a missing category approach.(32)  
Mixed effects linear regression 
For each continuous outcome, we applied mixed effects linear regression models to the 
matched samples, with a random effect for patient, to estimate the mean of the measure 
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over time, for each treatment group. We fitted a cubic model for the outcome over time. 
Follow-up time was split at 12, 24, 36, 60, 84 and 96 weeks, with cut-offs based on 
commonly reported time periods in clinical trials. Treatment effects were estimated 
separately in each time band. We used these models to estimate differences in means at 
12 and 60 weeks compared to week zero. Overall differences across the 96-week period 
were obtained by averaging the period-specific treatment effect estimates and weighting 
by the duration of the period. To explore differential drop out over follow up, we 
calculated mean baseline level of HbA1c, eGFR, systolic BP and BMI for all patients 
remaining in the analysis population at each follow up time point. 
Sensitivity analyses 
To assess the robustness of results to the assumptions made in our primary analysis we 
completed a series of sensitivity analyses. First, we applied the mixed effects models to 
1:1:1 matched samples (rather than matched sets with varying numbers of matches). 
Second, we removed the censoring when patients were prescribed an additional or 
alternative diabetic medication, to obtain results analogous to an intention-to-treat-
estimate. Third, we assessed the impact of conducting a complete case analysis by 
imputing missing data using chained equations . Fourth, we restricted the analysis to 
patients who had at least one baseline and one follow-up measure for all four outcome 
measures, to determine whether the primary results were influenced by inclusion of 
patients without select measures into different cohorts. Fifth, we excluded individuals 
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from the analysis if they had high numbers of tests for each measure (eGFR, HbA1c, 
BMI or systolic BP) during follow-up to assess whether frequent measurements had an 
impact on the findings. 
Patient and Public Involvement statement 
Patients were not involved in the design or conduct of the study. We plan to disseminate 
the results through peer-reviewed publication.  




Within the study population, of individuals who intensified from metformin 
monotherapy with an SU, DPP4i or SGLT2i, 40% were female and the mean age, 
BMI, eGFR and systolic BP was 60 years, 33 kg/m2, 89 mls/min/1·73m2 and 133 
mmHg respectively. (Table 1) The subcohorts for each physiological variable of 
interest comprised: eGFR 5,067, HbA1c 5,392, BMI 6,587 and systolic BP 7,958 
individuals. Details of the cohort selection are provided in Figure 1.   
Propensity score matched analysis 
Initial imbalances in baseline characteristics across treatment groups were minimised 
after propensity score matching, for each cohort (HbA1c, eGFR, BMI and systolic 
BP) (Supplementary Figure 1). The propensity scores for SGLT2i showed 
substantial overlap across the three treatment groups (Supplementary Figure 2).  
Supplementary Table 1 describes the unmatched SGLT2i users and 
Supplementary Table 2 shows the number of matches identified for each cohort. 
The number of SGLT2i users not matched ranged from 3% in the BMI cohort to 
11% in the systolic BP cohort. The length of follow-up (days) and number of 
repeated measures did not vary substantially between each clinical variable 
(Supplementary Table 3).  
Table 2 provides the baseline characteristics of the largest propensity score matched 
cohort, that for HbA1c. Baseline characteristics for the eGFR, systolic BP and BMI 
matched cohorts are shown in Supplementary Tables 4-6. After propensity score 
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matching, cohorts were well matched on baseline covariates, and closely matched on 
the baseline physiological variables of interest. Supplementary Figure 2 show the 
percentage standardised mean difference in baseline covariates for unmatched and 
matched cohorts, for each measure.     
Estimated mean values of each clinical measure for each treatment group at the 
analysed time points, and changes from baseline, from linear mixed models fitted 
within the propensity-score matched cohorts are shown in Figure 2 and 
Supplementary Table 7. 
HbA1c fell substantially after intensification from a baseline of 76-77 mmol/mol for 
all drugs, but fall was greatest for SGLT2i users. The mean fall (mmol/mol) at week 
12 was -15·2 (95% CI: -16·9, -13.5) for SGLT2i users, SU -14.3 (95% CI: -15.5, -
13.2) for SU users and -11.9 (95% CI: -13.1, -10.6) for DPP4i users. This fall 
compared to baseline was similar at 60 weeks of follow-up for all drug classes. The 
mean difference (mmol/mol) over 96 weeks of follow-up for SGLT2i users was -5.4 
(95% CI: -7.4, -3.4) compared to DPP4i and -1.7 (95% CI: -3.7, +0.2) compared to 
SU. 
Baseline systolic BP was 134-135 mmHg and fell for SGLT2i users throughout 
follow-up but not DPP4i or SU users. The mean fall (mmHg) at week 12 was -2.3 
(95% CI: -3.8, -0.8) for SGLT2i users, -0.8 (95% CI: -1.9, +0.4) for SU users and -
0.9 (95% CI: -2.1, +0.2) for DPP4i users. At 60 weeks, systolic BP remained lower 
than baseline for SGLT2i users but not for other drug classes. The mean difference 
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(mmHg) over 96 weeks of follow-up for SGLT2i users was -1.82 (95% CI: -3.18, -
0.45) compared to DPP4i and -3.06 (95% CI: -4.43, -1.68) compared to SU. 
Mean BMI at baseline was 36-37 kg/m2 and fell compared to baseline over follow-
up for SGLT2i and DPP4i treated patients. The mean fall (kg/m2) at week 12 was -
0.7 (95% CI: -0.9, -0.5) for SGLT2i users, 0.0 (95% CI: -0.3, +0.2) for SU users and 
-0.3 (95% CI: -0.5, -0.1) for DPP4i users. At 60 weeks, BMI remained lower than 
baseline for SGLT2i and DPP4i users but not SU users. These falls in BMI are 
equivalent to a weight loss of 2.3 kg for a DPP4i user and 5.0 kg for an SGLT2i user 
at 60 weeks of treatment for a person 1.7 m tall, the mean height of the cohort of 
patients prescribed SGLT2is. The mean difference (kg/m2) over 96 weeks of follow-
up for SGLT2i users was -0.92 (95% CI: -1.17, -0.66) compared to DPP4i and -1.67 
(95% CI: -1.95, -1.38) compared to SU.  
Baseline eGFR was 95 mls/min/1.73m2 and fell at 12 weeks for SGLT2i and DPP4i 
treated patients. The mean fall (mls/min/1.73m2) at week 12 was -3.1 (95% CI: -4.1, 
-2.0) for SGLT2i users, +0.5 (95% CI: -0.4, +1.3) for SU users and -1.0 (95% CI: -
1.9, -0.2) for DPP4i users. At 60 weeks, the fall in eGFR from baseline was 
approximately 2 mls/min/1.73m2 for each drug class. The mean difference 
(mls/min/1.73m2) over 96 weeks of follow-up for SGLT2i users was -0.03 (95% CI: 
-1.01, 0.94) compared to DPP4i and -0.78 (95% CI: -1.82, -0.27) compared to SU. 
During, and at the end of follow-up, participants who remained in the cohort were 
similar in their baseline measure to the entire cohort at baseline, suggesting that 
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differential loss to follow up of patients whose health status varied importantly from 
the entire cohort had not occurred (Supplementary Tables 8-11). 
Results of all sensitivity analyses were all similar to the main analysis 
(Supplementary Figures 3-7 and Supplementary Table 12). Distribution of 
baseline covariates for individuals dropped due to missing baseline or follow-up 
measures are similar to the study population (Supplementary Tables 14-17).  




Our research has robustly estimated and compared the effects of the three drug 
options commonly used to intensify metformin monotherapy; SUs, SGLT2is and 
DPP4is, on HbA1c, BMI, systolic BP and eGFR in UK primary care. In cohorts of 
people with similar baseline characteristics and levels of each clinical measure we 
show that all three drug options were associated with large falls in HbA1c, with 
better overall glycaemic control for people prescribed SGLT2is. People prescribed 
both DPP4i and SGLT2i experienced falls in BMI that were sustained over the study 
duration, with those prescribed SGLT2is experiencing about twice the weight loss 
seen for DPP4i users. Systolic BP fell compared to baseline at 12 weeks for SGLT2i 
users but not for other drug classes. Over the study duration, systolic BP was 
approximately 3mmHg lower for those prescribed SGLT2i compared to those 
prescribed SU. However, confidence intervals for the estimates of systolic blood 
pressure are large and overlap for the SGLT2i and DPP4i cohorts. Users of SGLT2i 
demonstrated falls in eGFR at 12 weeks of treatment but over time the fall in eGFR 
was small and similar for each drug class.  
The major strength of this study is that it reflects recent clinical practice where 
relative equipoise about choice of drug class and wide national variation in choice 
create an opportunity for direct comparison of drug effects. Selecting patients having 
drug therapy intensified at the same stage of treatment reduces time related bias. We 
have previously examined the differences in patient characteristics prescribed each 
drug class in detail and, based on this, have used propensity score matching to 
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achieve cohorts of patients very similar in baseline characteristics. Regular 
monitoring of type 2 diabetic patients in UK primary care provided extensive data 
enabling us to use the vast majority of patients from our baseline cohort for 
modelling each clinical variable.  
However, the relatively short period over which SGLT2is have been used in UK 
primary care means that the sample size is smaller than for many primary care 
database studies with a follow-up of two years, shorter than recent clinical trials. 
This means that we can only examine class effects and would be underpowered to 
detect drug-specific effects and endpoints such as cardiovascular disease mortality. 
We classified the start date of treatment for each intensification drug from the first 
record in primary care. For a proportion where the drugs were initiated in secondary 
care, this date would be misclassified. Our ‘baseline’ values of physiological 
variables may therefore have been measured after treatment had started. However, 
this would have led to underestimation of early differences and given the short 
duration of prescriptions issued in secondary care we would anticipate that this 
would affect only a very small proportion of our results. Proteinuria data was 
insufficiently complete to use as a variable in our analysis. 
Our study design focussed on providing matches of patients prescribed DPP4i and 
SU to patients prescribed SGLT2i drugs. This means that the results are 
generalisable only to contemporary SGLT2i users in primary care who had, for 
example, high BMI and well preserved renal function compared to users of other 
drug classes. Patients with a relative contraindication for a drug, for example those 
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with poor renal function (and therefore prescribed DPP4i or SU) would not have 
been matched. Nonetheless, this study design does provide a robust comparison of 
the drug effects in routine care for patients for whom there was the possibility of 
patients being prescribed one of the three drug classes.  
Finally, we sought to study the biological effects of the drug classes, so censored 
follow-up when patients commenced treatment with an alternative drug class, 
analogous to an ‘as treated’ analysis of a clinical trial. If a greater proportion of 
patients stopped treatment with one of the drug classes this would limit validity of 
between drug comparisons, particularly if decision to stop treatment was associated 
with an outcome variable (such as failure for glycaemic control to improve). 
However, we saw similar results in our simulated ‘intention to treat’ analysis, where 
we did not censor patients when they changed treatment, suggesting that this has not 
substantially impacted our results. A small proportion of the cohort (4%) stop the initial 
drug and do not restart a different diabetic treatment (which would lead to censoring), 
clinical measures early on in the study period are likely to most closely represent the ‘as 
treated’ drug effects’ 
As we have shown previously, SGLT2is are prescribed to a different population in 
UK primary care compared to patients enrolled in recent major outcome trials 
(Supplementary Table 13).(23) Participants in our study were younger with better 
renal function and lower proportion of cardiovascular disease, heart failure and 
retinopathy. Our study population had poorer glycaemic control and were heavier at 
baseline compared to participants in recent cardiovascular outcome studies. Perhaps 
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related to this they also showed greater improvement after initiating SGLT2i 
compared to trial patients. We found a fall in HbA1c equivalent to 1.4% after 12 
weeks of treatment while clinical trial estimates ranged from -0.25% (95% CI: -0.31, 
-0.20) in CREDENCE to -0.58% (95% CI: 0.61, -0.56) in CANVAS. 
For patients commencing SGLT2i, our study estimated falls in BMI compared to 
baseline equivalent to weight loss of 2 kg at 12 weeks for an individual 1.7m tall. 
Outcome studies showed weight loss ranging from 1 kg at 12 weeks in CREDENCE 
to 2 kg at 6 months in DECLARE-TIMI. At the end of our study mean weight loss 
compared to baseline was 5 kg for SGLT2i users compared to 2 kg in CREDENCE 
and 4 kg in DECLARE-TIMI.  
Falls in blood pressure and eGFR on initiating treatment with SGLT2is are well 
recognised and here we found striking similarities between the effects seen in 
clinical trials and in this routine care population, although there is substantial 
uncertainty around our estimates. We found a mean fall in systolic BP of 2.3 mmHg 
(95% CI: -3.8, -0.8) compared to baseline at 12 weeks for SGLT2i users but no fall 
for those prescribed other drug classes. Trial falls in systolic BP compared to 
baseline ranged from 2.8 mmHg at 12 weeks in the CREDENCE study to 5.5 mmHg 
in EMPA-REG (10mg dose arm). Over the duration of the study our results showed 
a mean difference in systolic BP of -3.06 mmHg (95% CI: -4.43, -1.68) compared to 
SU treated patients. Estimates compared to placebo in clinical trials were very 
similar ranging from -2.7 mmHg (95% CI: -3.0, -2.4) in the DECLARE-TIMI study 
to -3.93mmHg (95% CI: -4.30, -3.56) in CANVAS.  
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For renal function we found a fall in eGFR of -3.1 mls/min/1.73 m2 (95% CI: -4.1, -
2.0) at 12 weeks, similar to that seen at three weeks (-3.72 ± 0.25 mls/min/1.73 m2) 
in CREDENCE and the same as that seen in CANVAS at 12 weeks (-3.1 ± 0.1 
mls/min/1.73 m2). At 60 weeks we saw a fall of -2.2 mls/min/1.73 m2 (95% CI: -3.6, 
-0.7), again very similar to estimates seen in clinical trials, for example a slope of 
2.74 mls/min/1.73 m2 /year (95% CI: 2.37, 3.11) seen in CREDENCE. However, 
unlike the clinical trials, falls in eGFR in our comparison patient group were not 
different to SGLT2i treated patients, approximately 2mls/min/1.73 m2 at 60 weeks 
for patients treated with both SU and DPP4i. By contrast placebo treated patients in 
CREDENCE had a slope of decline of renal function of -4.59 mls/min/1.73 m2 /year 
while in CANVAS they had a difference from baseline of -3.9 ± 0.2 mls/min/1.73 m2 
at a mean follow-up of 188 weeks in CANVAS. 
These results demonstrate the huge value of primary care data for conducting 
observational research. Providing validation to our methods, estimates for both 
improvement in glycaemic control and HbA1c were very similar to those found in 
previous research on intensification of treatment for type 2 diabetes using 
CPRD.(19) This is the first study to examine how changes in BP and renal function 
relate to changes observed in clinical trials using CPRD data. Given the consistency 
of the results they are reassuring that the benefits of SGLT2i seen in clinical trials 
will be maintained in routine care, although given the lower risk profile of SGLT2i 
treated patients evidence of hard outcome benefits may take longer to accrue. This is 
particularly the case for outcomes related to renal function where our results suggest 
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that rate of renal decline is slower in non SGLT2i treated patients than in clinical 
trials which may reflect the overall lower risk profile (younger with higher baseline 
eGFR) or the tighter glycaemic control seen in patients treated with other active 
agents in routine care.  
In conclusion, routine primary care data can be used to study the effect of the new 
classes of treatments for type 2 diabetes on a range of biological variables, and 
provides estimates that are directly comparable to those seen in controlled clinical 
trials. Although SGLT2is are associated with the largest reductions in glycaemic 
control, weight, and blood pressure, both SUs and DPP4is are also associated with 
beneficial changes, reinforcing the need for active comparator outcome trials of these 
drugs. 
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N = 5,010 
SGLT2i 
N = 1,187 
DPP4i 
N = 4,434 
Age (years)  61 (13) 55 (10) 61 (12) 
Female  1988 (39.7) 474 (39.9) 1745 (39.4) 
BMI (kg/m2)  32 (6) 37 (7) 33 (7) 
Missing  470 (9.4) 54 (4.5) 285 (6.4) 
eGFR (mls/min/1.73m2)  89 (18) 96 (13) 88 (18) 
Missing  1683 (33.6) 493 (41.5) 1568 (35.4) 
Systolic BP (mmHg)  133 (14) 134 (14) 133 (14) 
Missing  837 (16.7) 293 (24.7) 880 (19.8) 
HbA1c (mmol/mol)  80 (21) 77 (17) 73 (16) 
Missing  2180 (43.5) 629 (53) 2085 (47) 
Metformin treatment 
(months) 
 40 (37) 36 (33) 44 (37) 
Cardiovascular disease  707 (14.1) 119 (10) 601 (13.6) 
Heart failure  194 (3.9) 24 (2) 146 (3.3) 
Retinopathy  868 (17.3) 181 (15.2) 861 (19.4) 
ACEI/ARB treatment  2711 (54.1) 670 (56.4) 2490 (56.2) 




LEAST deprived 1 467 (9.3) 93 (7.8) 398 (9.0) 
2 485 (9.7) 99 (8.3) 378 (8.5) 
 3 567 (11.3) 117 (9.9) 449 (10.1) 
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 4 643 (12.8) 99 (8.3) 427 (9.6) 
 MOST deprived 5 589 (11.8) 81 (6.8) 479 (10.8) 
Missing  2259 (45.1) 698 (58.8) 2303 (51.9) 
  
SU 
N = 5,010 
SGLT2i 
N = 1,187 
DPP4i 
N = 4,434 
Smoking status Non-smoker 1883 (37.6) 462 (38.9) 1642 (37.0) 
Current 818 (16.3) 193 (16.3) 688 (15.5) 
Ex-smoker 2297 (45.8) 532 (44.8) 2102 (47.4) 
Missing  12 (0.2) N<5 N<5 
Ethnicity White 2052 (41.5) 500 (42.1) 1944 (43.8) 
 South Asian 229 (4.6) 31 (2.6) 146 (3.3) 
 Black 122 (2.4) 9 (0.8) 61 (1.4) 
 Other 59 (1.2) 5 (0.4) 26 (0.6) 
 Mixed heritage 14 (0.3) N<5 16 (0.4) 
Missing  2534 (50.6) 640 (53.9) 2241 (50.5) 
Table 1. Description of the study population at baseline for individuals 
intensifying treatment from metformin monotherapy with SU, SGLT2i or 
DPP4i between 2014-2017 
Values for continuous values are mean (standard deviation) and categorical values are n (%). 
% are of entire cohort. Abbreviations: SU: Sulfonylurea, DPP4i: dipeptidyl peptidase 4 
inhibitors, SGLT2i: Sodium-glucose co-transporter-2 inhibitors, HbA1c: Haemoglobin A1c, 
eGFR: estimated glomerular filtration rate, BMI: Body mass index, BP: Blood pressure, 
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ACEI: Angiotensin converting enzyme inhibitor, ARB: Angiotensin 2 receptor blockers. 
Frequencies below five not stated as per MHRA Database Research policy.   
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  SU SGLT2i DPP4i 
Number of individuals*  1,691 481 1,445 
Counts after weighting  481 481 481 
Age (years)  56.4 (11.3) 56.3 (9.6) 56.6 (10.6) 
Female  191 (40) 191 (40) 190 (39) 
BMI (kg/m2)  34.4 (5.4) 34.8 (5.5) 34.3 (5.4) 
eGFR (mls/min/1.73m2)  93.5 (15.4) 93.3 (12.2) 93.3 (14.7) 
Systolic BP (mmHg)  133.9 (13.3) 133.7 (12.4) 133.7 (13.2) 
HbA1c (mmol/mol)  76.7 (18.2) 76.4 (16.8) 76.7 (16.6) 
Metformin treatment 
(months) 
 36.1 (34.4) 38.0 (32.9) 38.2 (35.2) 
Cardiovascular disease  57 (12) 45 (9) 51 (11) 
Heart failure  14 (3) 12 (2) 11 (2) 
Retinopathy  79 (16) 75 (16) 88 (18) 
ACEI/ARB treatment  252 (52) 278 (58) 252 (52) 




LEAST deprived 1 50 (10) 51 (11) 50 (10) 
2 51 (11) 54 (11) 51 (11) 
 3 59 (12) 60 (12) 61 (13) 
 4 41 (9) 40 (8) 37 (8) 
 MOST deprived 5 35 (7) 37 (8) 36 (7) 
Missing  245 (51) 239 (50) 246 (51) 











  SU SGLT2i DPP4i 
Smoking status Non-smoker 178 (37) 199 (41) 182 (38) 
Current 87 (18) 75 (16) 73 (15) 
Ex-smoker 213 (44) 207 (43) 225 (47) 
Missing  <5 < 5 < 5 
Ethnicity White 202 (42) 194 (40) 192 (40) 
 South Asian 9 (2) 11 (2) 11 (2) 
 Black 6 (1) 7 (1) 6 (1) 
 Other < 5 < 5 < 5 
 Mixed heritage < 5 < 5 < 5 
Missing  261 (54) 267 (56) 269 (56) 
Table 2. Description of the propensity score matched and weighted HbA1c 
cohort at baseline for individuals intensifying treatment from metformin 
monotherapy with SU, SGLT2i or DPP4i between 2014-2017 
*Number of individuals contributing data to the HbA1c analysis, before weighting was applied. 
Values for categorical values are weighted mean (standard deviation) and categorical values are n (%) 
of entire cohort. After iteration of the propensity score model, the following covariates were included 
in the model: age, HbA1c, eGFR, BMI, systolic BP, patient-level IMD, ethnicity. The groups were 
further matched on deciles of baseline HbA1c. Figures provided are weighted means or counts. 
Abbreviations: SU: Sulfonylurea, DPP4i: dipeptidyl peptidase 4 inhibitors, SGLT2i: Sodium-glucose 
co-transporter-2 inhibitors, HbA1c: Haemoglobin A1c, eGFR: estimated glomerular filtration rate, 
BMI: Body mass index, BP: Blood pressure, ACEI: Angiotensin converting enzyme inhibitor, ARB: 
Angiotensin 2 receptor blockers. Frequencies below five not stated as per MHRA Database Research 
policy.  
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